Transrectal ultrasound-guided systematic (TRUS) biopsy is commonly used in clinical practice to detect clinically significant prostate cancer (PCa)[1-3]. In this study, a more advanced biopsy, MRI-TRUS fusion targeted biopsy, is used together with MRI-derived PI-RADS V2 scoring system for the diagnosis of clinical significant PCa. The values of the two biopsy methods are compared.
This abstract and the presentation materials are available to members only; a login is required.